Phathom Pharmaceuticals (NASDAQ:PHAT) Given New $25.00 Price Target at Guggenheim

Phathom Pharmaceuticals (NASDAQ:PHAT) had its price target increased by Guggenheim from $20.00 to $25.00 in a report issued on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

PHAT has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a report on Thursday, January 22nd. Raymond James Financial initiated coverage on shares of Phathom Pharmaceuticals in a research note on Thursday, December 11th. They issued a “strong-buy” rating and a $28.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Phathom Pharmaceuticals in a report on Wednesday, January 14th. HC Wainwright raised their target price on shares of Phathom Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Finally, Barclays began coverage on shares of Phathom Pharmaceuticals in a research report on Monday, December 8th. They issued an “equal weight” rating and a $16.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Phathom Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.25.

Phathom Pharmaceuticals Price Performance

Shares of NASDAQ PHAT traded down $1.00 during mid-day trading on Friday, reaching $12.56. 1,182,096 shares of the company traded hands, compared to its average volume of 947,573. Phathom Pharmaceuticals has a fifty-two week low of $2.21 and a fifty-two week high of $18.31. The firm has a market cap of $897.04 million, a PE ratio of -4.10 and a beta of 0.51. The stock has a fifty day simple moving average of $14.30 and a 200-day simple moving average of $13.47.

Phathom Pharmaceuticals (NASDAQ:PHAT) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. The firm had revenue of $57.58 million for the quarter, compared to the consensus estimate of $57.44 million. As a group, analysts predict that Phathom Pharmaceuticals will post -4.78 EPS for the current fiscal year.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Several hedge funds have recently bought and sold shares of PHAT. Caitong International Asset Management Co. Ltd purchased a new position in Phathom Pharmaceuticals during the 4th quarter valued at about $27,000. Jones Financial Companies Lllp grew its position in Phathom Pharmaceuticals by 442.6% during the third quarter. Jones Financial Companies Lllp now owns 2,523 shares of the company’s stock valued at $30,000 after purchasing an additional 2,058 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Phathom Pharmaceuticals in the 2nd quarter worth approximately $30,000. Kestra Advisory Services LLC acquired a new stake in shares of Phathom Pharmaceuticals during the 4th quarter valued at $38,000. Finally, Ameritas Investment Partners Inc. boosted its stake in shares of Phathom Pharmaceuticals by 39.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,311 shares of the company’s stock valued at $41,000 after buying an additional 1,216 shares during the period. 99.01% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Phathom Pharmaceuticals

Here are the key news stories impacting Phathom Pharmaceuticals this week:

• Positive Sentiment: Guggenheim raised its price target to $25 and upgraded PHAT to a “buy”, implying large upside from current levels — a clear analyst endorsement that can support the stock over the medium term. Guggenheim PT Raise (Benzinga)
• Positive Sentiment: Management issued FY‑2026 revenue guidance of $320M–$345M and reiterated a target of operating profitability beginning in Q3 2026 and for the full year — guidance above street revenue consensus and a near‑term path to profitability are constructive for valuation. 2026 Guidance (Seeking Alpha)
• Positive Sentiment: Q4 results beat: EPS of ($0.08) vs. consensus ($0.09) and revenue $57.6M vs. $57.4M; FY2025 revenue jumped to $175.1M (≈217% YoY) and VOQUEZNA® prescriptions topped 1.1M — evidence of strong commercial traction. Q4 Results & Press Release (GlobeNewswire)
• Neutral Sentiment: Company says it strengthened its balance sheet via a $130M equity offering and a term‑debt modification; management reported modest net cash usage — this improves runway but the equity raise can be dilutive, which may temper upside. Balance Sheet Update (GlobeNewswire)
• Neutral Sentiment: Earnings materials (presentation and call transcript) are available for review — useful for details on sales cadence, launch math and timing to profitability but not new headlines by themselves. Earnings Presentation (Seeking Alpha) Earnings Transcript (Seeking Alpha)
• Neutral Sentiment: Preview and analyst commentary published around the Q4 print are available for reading; they summarize expectations and may influence near‑term sentiment but contain no fresh operational surprises. Q4 Preview (Yahoo Finance)

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.